Ly3439539

Phase 1

Eli Lilly

Ly3439539 is one of 43 therapeutic programs targeting Alzheimer disease. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Alzheimer DiseaseRecruiting

Alzheimer DiseasePhase 1

Recruiting

Competition

Competitive Landscape

100 competitors in Alzheimer Disease

#DrugCompanyPhaseTrials

Leqembi

Eisai

Approved

1 2

Dayvigo

Eisai

Approved

1 3

Avandia

Estrace

Rifadin

Avelox

Victoza

Aleve

Epidiolex

Cialis

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Recruiting

Alzheimer Disease

NCT07598370

Clinical

Trials by Indication[1]

Alzheimer disease1 trial

A Phase 1, Open Label, Multiple-Dose Study to Assess the Changes in Cerebrospinal Fluid Biomarkers for Alzheimer's Disease Following Treatment With LY3439539 in Participants With Symptomatic Alzheimer's Disease

Recruiting· Eli Lilly logo

Eli Lilly·Phase 1·NCT07598370·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Ly3439539. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Ly3439539. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Eli Lilly company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: Eli Lilly

Ly3439539

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Alzheimer disease1 trial

References

Drug Info

Quick Facts

Related News